These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3134974)

  • 1. Augmentation of lymphokine-activated killer cell activity in patients with gastrointestinal cancer.
    Sedman PC; Ramsden CW; Brennan TG; Giles GR; Guillou PJ
    Br J Surg; 1988 Jun; 75(6):591-4. PubMed ID: 3134974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
    Matsunaga H; Kuwahara Y; Kusugami K; Morise K; Shimokata K
    Gastroenterol Jpn; 1988 Oct; 23(5):527-33. PubMed ID: 3145895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.
    Monson JR; Ramsden CW; Giles GR; Brennan TG; Guillou PJ
    Gut; 1987 Nov; 28(11):1420-5. PubMed ID: 3501386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
    Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
    Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
    Guillou P
    Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [LAK cells and cancer].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract]   [Full Text] [Related]  

  • 15. Modelling and simulation of Rosenberg-type adoptive cellular immunotherapy.
    Nani FK; Oğuztöreli MN
    IMA J Math Appl Med Biol; 1994; 11(2):107-47. PubMed ID: 8089590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
    Richards JM
    Blood Rev; 1989 Jun; 3(2):110-9. PubMed ID: 2673443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).
    Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Takimoto H; Hayakawa T; Mogami H
    Acta Neurochir (Wien); 1988; 94(1-2):47-52. PubMed ID: 3177046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
    Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.
    Koyama S; Ebihara T; Fukao K; Osuga T
    Jpn J Cancer Res; 1989 Feb; 80(2):150-7. PubMed ID: 2498249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
    Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
    Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.